Study of the Efficacy and Safety of Letrozole Combined With Trastuzumab in Patients With Metastatic Breast Cancer
Phase IV trial to investigate the effect of the combination of Letrozole with trastuzumab in metastatic breast cancer patients
Metastatic Breast Cancer
DRUG: Letrozole|DRUG: Trastuzumab plus Letrozole|DRUG: Letrozole
Time to progression as assessed by clinical palpation and radiologic imaging every 3 months, 3 months
Objective response rate/Clinical Benefit rate, 3 months|Time to treatment failure, 3 months|Duration of response/clinical benefit during treatment, 3 months|Overall survival, 3 months
Phase IV trial to investigate the effect of the combination of Letrozole with trastuzumab in metastatic breast cancer patients